Target intelligence / Profile preview

Target of RNAIII-activating protein (TRAP) (TRAP)

Target
TRAP
Molecular classification
Bacterial signal transduction protein, Virulence regulator
01

Overview

Target of RNAIII-activating protein (TRAP) is a 21 kDa membrane-associated protein in Staphylococcus aureus that has been identified as a master regulator of the bacteria's quorum-sensing and virulence pathways (Korem et al., 2003, PubMed: 12867450). According to the RAP/TRAP model, TRAP is phosphorylated in the presence of the RNAIII-activating protein (RAP), an autoinducer secreted by the bacteria as population density increases (Balaban et al., 2001, PubMed: 11158668). This phosphorylation event is described as a prerequisite for the activation of the accessory gene regulator (agr) system, which controls the expression of RNAIII and subsequent virulence factors like alpha-toxin (Gov et al., 2001, PubMed: 11274107). While the RAP/TRAP signaling model has been a subject of scientific debate regarding its integration with the canonical agr system, TRAP remains a significant target for anti-virulence drug development (Balaban et al., 2003, PubMed: 12654481). Therapeutic agents like the RNAIII-inhibiting peptide (RIP) work by competitively inhibiting the phosphorylation of TRAP, thereby suppressing toxin production (Yang et al., 2006, PubMed: 16410547). This approach aims to treat multidrug-resistant S. aureus infections by disarming the pathogen's virulence machinery rather than killing the bacteria directly.

Other names
TRAPRNAIII-activating protein targetTraP proteinStaphylococcal TRAP
02

Mechanism of action

Inhibition of TRAP phosphorylation to prevent activation of the accessory gene regulator (agr) system and subsequent virulence factor production.

03

Biological functions

Quorum sensingRegulation of virulence factorsBiofilm formationSignal transduction
04

Disease associations

Staphylococcus aureus infectionMethicillin-resistant Staphylococcus aureus (MRSA) infectionSepsisSkin and soft tissue infection
05

Safety considerations

Potential for off-target effects on host microbiomeBioavailability and stability of peptide-based inhibitorsScientific debate regarding the integration of the RAP/TRAP model with the canonical agr systemBacterial adaptation through alternative regulatory pathways
06

Interacting drugs

RNAIII-inhibiting peptide (RIP)

2 more in the full profile.

07

Biomarkers

RNAIII expression levelsAlpha-hemolysin (Hla) levelsTRAP phosphorylation status

Beyond the preview

Go deeper on Target of RNAIII-activating protein (TRAP) (TRAP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target of RNAIII-activating protein (TRAP) (TRAP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call